{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:45:14Z","timestamp":1793371514113,"version":"4.5.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010888","name":"Wuhan Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["2023020201010184"],"award-info":[{"award-number":["2023020201010184"]}],"id":[{"id":"10.13039\/501100010888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014717","name":"Youth Science Fund Project","doi-asserted-by":"publisher","award":["82402109"],"award-info":[{"award-number":["82402109"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Department of Science and Technology of Hubei Province","doi-asserted-by":"publisher","award":["2025\u5e74AFC133"],"award-info":[{"award-number":["2025\u5e74AFC133"]}],"id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010849","name":"Health and Family Planning Commission of Wuhan Municipality","doi-asserted-by":"publisher","award":["WX23B13"],"award-info":[{"award-number":["WX23B13"]}],"id":[{"id":"10.13039\/501100010849","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to assess the efficacy and safety of tofacitinib and tacrolimus (TAT) combination therapy for treating refractory interstitial lung disease (ILD) associated with anti-synthetase syndrome (ASyS-ILD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Patients with refractory ASyS-ILD who were treated with TAT at Wuhan No. 1 Hospital were included in the study from January 2020 to May 2024.\u00a0A retrospective analysis of the clinical data from these patients is presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      A total of six patients, one male patient and five female patients, primarily presented with refractory ASyS-ILD. All patients experienced symptomatic relief following TAT therapy, which facilitated the successful tapering of glucocorticoids (GCs, 24.67 \u00b1 17.42\n                      <jats:italic>vs.<\/jats:italic>\n                      8.34 \u00b1 1.89,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.004). After treatment, PGA, PGA-VAS, PhGA-VAS, and MMT-8 scores significantly improved, and diffusing capacity of carbon monoxide (DLCO) increased in all 6 patients. Moreover, the serum levels of creatine kinase (CK) and lactate dehydrogenase (LDH) were notably reduced, and inflammatory indices, including C-reactive protein (CRP), ferritin, and erythrocyte sedimentation rate (ESR), declined significantly in all patients after administration of TAT. Additionally, peripheral white blood cell and neutrophil counts were significantly reduced, while lymphocyte counts increased, with a markedly decreased neutrophil\/lymphocyte ratio in patients with ASyS-ILD receiving treatment. However, during treatment, two patients developed herpes zoster, which resolved with antiviral treatment. Unfortunately, two fatalities occurred, one due to disease progression from severe\n                      <jats:italic>Aspergillus fumigatus<\/jats:italic>\n                      pneumonia and the other due to pancreatic cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this series of patients with refractory ASyS-ILD, TAT therapy showed some clinical effectiveness over the short term, with an observed steroid-sparing outcome, suggesting a possible benefit. Nevertheless, larger prospective controlled studies are necessary to further assess its efficacy and safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1847006","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:42:04Z","timestamp":1788417724000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of tofacitinib and tacrolimus therapy in refractory interstitial lung disease associated with anti-synthetase syndrome: a case series of six patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Qiuyu","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Immunology, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohui","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Medicine Imaging, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Immunology, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Immunology, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Immunology, Wuhan No. 1 Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Med (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/77.1.1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"Q J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084453","article-title":"A review of antisynthetase syndrome-associated interstitial lung disease","volume":"25","author":"Patel","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PloS One"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.105920","article-title":"Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review","volume":"165","author":"Liu","year":"2020","journal-title":"Respir Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600622884","article-title":"Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies","volume":"39","author":"Yoshifuji","year":"2006","journal-title":"Autoimmunity"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3854-8","article-title":"Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study","volume":"37","author":"Nakazawa","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.2889","article-title":"Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies","volume":"49","author":"Koreeda","year":"2010","journal-title":"Intern Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12890-016-0325-y","article-title":"Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy","volume":"16","author":"Sasano","year":"2016","journal-title":"BMC Pulm Me"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.resinv.2019.10.004","article-title":"Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease","volume":"58","author":"Takei","year":"2020","journal-title":"Respir Investig"},{"key":"B14","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151959","article-title":"Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review","volume":"53","author":"McPherson","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf046","article-title":"Tofacitinib treatment for active dermatomyositis and anti-synthetase syndrome: a prospective cohort pilot study","volume":"64","author":"Xing","year":"2025","journal-title":"Rheumatol (Oxford)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1590\/s1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001","volume":"165","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152474","article-title":"Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: a retrospective cohort study","volume":"68","author":"Shan","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-025-07398-9","article-title":"Clinical features and risk factors of flare in anti-synthetase syndrome","volume":"44","author":"Hasegawa","year":"2025","journal-title":"Clin Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-1401","article-title":"Lung CT densitometry in systemic sclerosis: correlation with lung function, exercise testing, and quality of life","volume":"131","author":"Camiciottoli","year":"2007","journal-title":"Chest"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000663","article-title":"Pulmonary involvement in antisynthetase syndrome","volume":"31","author":"Gasparotto","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103879","article-title":"Remission and low disease activity definitions in adult idiopathic inflammatory myopathies: a narrative review by myositis clinical trials consortium (MCTC)","volume":"24","author":"Pongtarakulpanit","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and TAC versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115848","article-title":"Synthesis and clinical application of small-molecule inhibitors of Janus kinase","volume":"261","author":"Zhang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/hxin6o","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2401488","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"key":"B31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.55563\/clinexprheumatol\/0yu9gm","article-title":"Janus kinase inhibitors therapy in idiopathi inflammatory myopathies: a case series","volume":"44","author":"Vasconcelos","year":"2026","journal-title":"Clin Exp Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.729602","article-title":"Description and analysis of a novel subtype of the anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa895","article-title":"The safety of JAK-1 inhibitors","volume":"60","author":"Clarke","year":"2021","journal-title":"Rheumatol (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1847006\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:42:06Z","timestamp":1788417726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1847006\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1847006"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1847006","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1847006"}}